The most common driving mutations observed in NSCLC correspond to the ones found in epidermal growth factor receptor (EGFR), KRAS, human epidermal growth factor receptor 2 (HER2), and EML4-ALK translocations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.